Introducing 

Prezi AI.

Your new presentation assistant.

Refine, enhance, and tailor your content, source relevant images, and edit visuals quicker than ever before.

Loading…
Transcript

ERIS

EARNINGS PERFORMANCE

Q4FY20

REVENUE

PREVIOUS PERIOD

CURRENT PERIOD

248

227

+9.25%

REVENUE

REVENUE

Eris Lifesciences posted a decent set of earnings performance. Consolidated total income increased by 9.25% at Rs. 247.50 Crs as compared to Rs. 226.55 Crs in the corresponding quarter previous year. Sale of products grew by 15.63% whereas other operating income increased by 19.94% on a YoY basis.

In Q4FY20, Chronic segment constitutes 65% of Company's revenue, Sub-chronic segment constitutes 22% of revenue and Acute segment is 13% of Company's revenue.

Chronic therapies continue to outperform market and sub chronic therapies regain momentum: chronic therapies grow 19.6% YoY vs. IPM growth of 12.1% whereas sub chronic therapies grow 13.4% YoY vs. IPM growth of 7.3%.

EBITDA

PREVIOUS PERIOD

CURRENT PERIOD

76

74

+3.10%

EBITDA

EBITDA

The company reported increase in EBITDA by 3.10% to Rs. 76.17 Crs as compared to Rs. 73.88 Crs in the previous year same quarter.

Company's EBITDA margin stood at 30.77%

PROFIT

PREVIOUS PERIOD

CURRENT PERIOD

56

54

+4.43%

PROFIT

PROFIT

Company reported a consolidated profit of Rs. 56.27 Crs vs. Rs. 53.88 Crs in the corresponding quarter previous year, a jump of 4.43%.

Cash flow from operations improved during the FY2019-20 with net cash inflow from operations of Rs. 271.11 Crs vs. Rs. 223 Crs during FY2018-19.

SUMMARY

PREVIOUS

CURRENT

248

227

BEATS

REVENUE

-9.25%

76

74

+3.10%

BEATS

EBITDA

56

54

+4.43%

BEATS

PROFIT

SHAREMARKET IMPACT

Learn more about creating dynamic, engaging presentations with Prezi